Marie-France Tschudin steps down

[anonymous]

• After nearly seven years at Novartis and more than four years as a member of the ECN, Ms. Tschudin will pursue her next chapter of leadership outside of Novartis

• Dr. Horber to drive next phase of international growth, shape commercial strategy, and continue Novartis leadership in reimagining medicines for patients around the world

Basel, September 06, 2023 — Novartis today announced that Marie-France Tschudin, President, Innovative Medicines International and Chief Commercial Officer, has decided to leave the company and will step down from the Executive Committee of Novartis (ECN), effective September 15, after nearly seven years of commercial leadership at Novartis. Patrick Horber, M.D., currently Senior Vice President and President, Immunology at AbbVie has been appointed as President, International, effective later this year, reporting to Vas Narasimhan, M.D., CEO of Novartis. Dr. Horber will become a member of the ECN. Mukul Mehta, Chief Financial Officer, International, will lead the unit ad-interim until Dr. Horber assumes the role.

“I leave Novartis with a strong sense of pride and accomplishment in how we have delivered on our purpose,” Marie-France Tschudin said. “My deep esteem and gratitude go to the Novartis colleagues around the globe for their trust, hard work, and relentless efforts in getting patients the treatments they need, faster.”

Vas Narasimhan said: “I want to thank Marie-France for her extraordinary leadership during her nearly seven years at Novartis. She has been integral to reimagining our commercial model and the way we deliver innovative medicines to patients around the world. Marie-France has led her teams to remarkable growth. The impact she has had on our business, on our people, and on patients around the world will be long-lasting. I wish her the very best as she pursues her next chapter.”

“I look forward to welcoming Patrick to Novartis. He is a proven leader with deep experience enabling commercial performance on a global scale, and I am confident he will catalyze our growth journey as Novartis enters our next chapter as a fully focused innovative medicines company.”

Patrick Horber said: "As a Swiss medical doctor, it is a privilege to join Novartis—a pillar of global biomedical innovation and scientific progress. I look forward to working alongside our teams to reimagine medicine for and with patients around the globe.”

Dr. Horber holds a M.D. from the University of Zurich. He is a native of Switzerland with over 20 years of experience in the biopharma sector and a deep understanding of the global pharmaceutical market. In his latest role as Senior Vice President and President, Immunology, at AbbVie, Dr. Horber was responsible for their Immunology Business Unit, leading the Global Strategy and U.S. execution including Global Commercial Development. Prior to this role he has served in a variety of leadership and general management positions in the US and Europe.

 

[anonymous]

• After nearly seven years at Novartis and more than four years as a member of the ECN, Ms. Tschudin will pursue her next chapter of leadership outside of Novartis

• Dr. Horber to drive next phase of international growth, shape commercial strategy, and continue Novartis leadership in reimagining medicines for patients around the world

Basel, September 06, 2023 — Novartis today announced that Marie-France Tschudin, President, Innovative Medicines International and Chief Commercial Officer, has decided to leave the company and will step down from the Executive Committee of Novartis (ECN), effective September 15, after nearly seven years of commercial leadership at Novartis. Patrick Horber, M.D., currently Senior Vice President and President, Immunology at AbbVie has been appointed as President, International, effective later this year, reporting to Vas Narasimhan, M.D., CEO of Novartis. Dr. Horber will become a member of the ECN. Mukul Mehta, Chief Financial Officer, International, will lead the unit ad-interim until Dr. Horber assumes the role.

“I leave Novartis with a strong sense of pride and accomplishment in how we have delivered on our purpose,” Marie-France Tschudin said. “My deep esteem and gratitude go to the Novartis colleagues around the globe for their trust, hard work, and relentless efforts in getting patients the treatments they need, faster.”

Vas Narasimhan said: “I want to thank Marie-France for her extraordinary leadership during her nearly seven years at Novartis. She has been integral to reimagining our commercial model and the way we deliver innovative medicines to patients around the world. Marie-France has led her teams to remarkable growth. The impact she has had on our business, on our people, and on patients around the world will be long-lasting. I wish her the very best as she pursues her next chapter.”

“I look forward to welcoming Patrick to Novartis. He is a proven leader with deep experience enabling commercial performance on a global scale, and I am confident he will catalyze our growth journey as Novartis enters our next chapter as a fully focused innovative medicines company.”

Patrick Horber said: "As a Swiss medical doctor, it is a privilege to join Novartis—a pillar of global biomedical innovation and scientific progress. I look forward to working alongside our teams to reimagine medicine for and with patients around the globe.”

Dr. Horber holds a M.D. from the University of Zurich. He is a native of Switzerland with over 20 years of experience in the biopharma sector and a deep understanding of the global pharmaceutical market. In his latest role as Senior Vice President and President, Immunology, at AbbVie, Dr. Horber was responsible for their Immunology Business Unit, leading the Global Strategy and U.S. execution including Global Commercial Development. Prior to this role he has served in a variety of leadership and general management positions in the US and Europe.

 

[anonymous]

The dominos begin to fall, ad they should.

 

[anonymous]

A lot more people need to go beyond her. They need to clean house from the top all the way down to Des! This place is on fire and they need to do something fast to save it.

 

[anonymous]

A lot more people need to go beyond her. They need to clean house from the top all the way down to Des! This place is on fire and they need to do something fast to save it.

 

[anonymous]

A lot more people need to go beyond her. They need to clean house from the top all the way down to Des! This place is on fire and they need to do something fast to save it.

Vas and Victor need to go.

 

[anonymous]

She was forced to step down- Victor in the line of fire next.

 

[anonymous]

Best news ever. The worst leader I’ve ever met. She had no soul.

 

[anonymous]

Satan of Darkness has left the building. Let us rejoice a new day and a leader who is competent.

 

[anonymous]

Vas and Victor need to go.

It is tough to say what Vas actually does, but Victor needed to go two years ago. Whether he likes it or not, the abject failure of C.V. falls squarely on him.
He stood by haplessly and watched as Dez, Duane, Jeff and Sandeep dragged the division into the sewer.
He could have cleaned up the disaster at the top at any time, but instead he fucked around with his camera and pretended everything was fine.
It wasn't. It would be nice to see his head on a pike next to hers.

 

[anonymous]

What would this company look like today if Paul stayed and Vas left??? The person who needs to be replaced is Joerg.

 

[anonymous]

signs that T4G, #5 by 25 a colossally huge failure. victor needs to go next.

 

[anonymous]

signs that T4G, #5 by 25 a colossally huge failure. victor needs to go next.[/QUOTE

Too bad this change didn’t come before all MF’s handpicked appointments. There is a mess to clean up.

 

[anonymous]

Vas and Victor need to go.

100% they both need to go. The amount of shit we are being put through is beyond imagination.

 

[anonymous]

Des came out of these changes on top. He now leads the oncology and pharma field forces.

 

[anonymous]

Wait what happened to lakisha or whatever her name is that used to head up onco?

 

[anonymous]

Wait what happened to lakisha or whatever her name is that used to head up onco?

You sound pretty racist, so I’m sure you’ll be thrilled she got promoted to leading commercial for all TAs.

 

[anonymous]

You sound pretty racist, so I’m sure you’ll be thrilled she got promoted to leading commercial for all TAs.

Racist because of making fun of a name? You do know the difference right?

 

[anonymous]

Someone running oncology without a lick of oncology experience. Makes sense at NVS.

 

[anonymous]

What the fuck was up with that useless townhall today. More useless than usual